featured

Join Us in Orlando for PPMD’s 30th Annual Conference

Celebrate three decades of progress, community, and resilience at PPMD’s 30th Annual Conference, June 27–29, 2024 in Orlando, Florida! Back in 1994, our very first Conference was held in Orlando, and now, 30 years later,…

Learn More

Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne

PPMD is pleased to learn of the U.S. commercial launch of AGAMREE® (vamorolone) oral suspension 40 mg/mL for the treatment of Duchenne in patients aged two years and older. According to Catalyst Pharmaceuticals, Inc., following…

Learn More

PPMD Celebrates 30th Anniversary and Three Decades of Progress with Annual Advocacy Conference

Over the past three decades, PPMD has driven Congress to enact legislation that has transformed federal public health, research, therapy development and access policies to bring us closer to ending Duchenne. This advocacy work has resulted…

Learn More

February 27, 2024

Breaking News: Rare Disease Day Congressional Hearing to Address the BENEFIT Act

On Thursday, February 29th, Rare Disease Day, the House Energy and Commerce Committee will hold a congressional hearing, titled “Legislative Proposals to Support Patients with Rare Diseases” at 10:00 am ET. This hearing will review…

Learn More

February 23, 2024

Watch: Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences (Webinar Recording)

Wave Life Sciences recently joined PPMD for a community webinar to share an update on the company’s FORWARD-53 study. Wave provided an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular…

Learn More

February 21, 2024

PPMD Announces Pediatric Certified Duchenne Care Center at Penn State Health Children’s Hospital

Today PPMD announced the expansion of our renowned Certified Duchenne Care Center (CDCC) Program with the certification of the clinic at Penn State Health Children’s Hospital in Hershey, Pennsylvania. This designation marks a significant step…

Learn More

February 16, 2024

FDA Accepts Efficacy Supplement to Expand ELEVIDYS Indication

PPMD is excited to learn that the U.S. Food and Drug Administration (FDA) has accepted and filed Sarepta Therapeutics’ efficacy supplement to the Biologics License Application (BLA) for ELEVIDYS. The efficacy supplement aims to expand…

Learn More

February 14, 2024

WATCH: PTC Therapeutics — EMFLAZA® Landscape in 2024 (Webinar Recording)

PPMD was recently joined by the team at PTC Therapeutics to discuss upcoming changes and continuing community support around EMFLAZA (deflazacort). EMFLAZA came on the U.S. market in 2017 as the first FDA-approved steroid specifically…

Learn More

February 13, 2024

PPMD Provides $500,000 in Funding to Kinea Bio Through PPMD Venture Pathways Program to Support Next-Gen Midi-Dystrophin Gene Therapy Development

PPMD is excited to announce that the organization has provided $500,000 in funding to Kinea Bio, Inc. (Kinea) through PPMD Venture Pathways, the organization’s venture philanthropy program which provides industry funding to accelerate therapeutic development….

Learn More

February 9, 2024

Update From PPMD’s 2024 PPMD Duchenne Healthcare Professionals Summit

PPMD recently hosted our fifth in-person Duchenne Healthcare Professionals Summit in Sanibel, FL. Over the course of three impactful days, we were joined by around 300 healthcare professionals, researchers, and industry partners to collaborate, connect,…

Learn More

Join Our Mailing List